133 related articles for article (PubMed ID: 35435090)
1. The use of hydroxyurea in the real life of MIOT network: an observational study.
Ricchi P; Meloni A; Rigano P; Pistoia L; Spasiano A; Allò M; Messina G; Quarta A; Rosso R; Quota A; Filosa A; Maggio A; Pepe A
Expert Opin Drug Saf; 2022 Nov; 21(11):1433-1440. PubMed ID: 35435090
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia: a comprehensive single-center experience.
Karimi M; Zarei T; Bahmanimehr A; Aramesh A; Daryanoush S; Haghpanah S
Ann Hematol; 2021 Dec; 100(12):2901-2907. PubMed ID: 34383102
[TBL] [Abstract][Full Text] [Related]
3. Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years' follow-up in Egypt.
El-Beshlawy A; El-Ghamrawy M; EL-Ela MA; Said F; Adolf S; Abdel-Razek AR; Magdy RI; Abdel-Salam A
Ann Hematol; 2014 Dec; 93(12):2045-50. PubMed ID: 25062719
[TBL] [Abstract][Full Text] [Related]
4. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran.
Karimi M; Darzi H; Yavarian M
J Pediatr Hematol Oncol; 2005 Jul; 27(7):380-5. PubMed ID: 16012328
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients.
Elalfy MS; Adly AA; Ismail EA; Elhenawy YI; Elghamry IR
Eur J Haematol; 2013 Dec; 91(6):522-33. PubMed ID: 23927461
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea for nontransfusion-dependent β-thalassemia: A systematic review and meta-analysis.
Algiraigri AH; Wright NAM; Paolucci EO; Kassam A
Hematol Oncol Stem Cell Ther; 2017 Sep; 10(3):116-125. PubMed ID: 28408107
[TBL] [Abstract][Full Text] [Related]
7. Hematologic response to hydroxyurea therapy in children with beta-thalassemia major.
Mtvarelidze Z; Kvezereli-Kopadze A; Kvezereli-Kopadze M; Mestiashvili I
Georgian Med News; 2008 Mar; (156):91-4. PubMed ID: 18403819
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea for lifelong transfusion-dependent β-thalassemia: A meta-analysis.
Algiraigri AH; Wright NAM; Paolucci EO; Kassam A
Pediatr Hematol Oncol; 2017 Nov; 34(8):435-448. PubMed ID: 29337597
[TBL] [Abstract][Full Text] [Related]
9. Response to hydroxyurea therapy in beta-thalassemia.
Koren A; Levin C; Dgany O; Kransnov T; Elhasid R; Zalman L; Palmor H; Tamary H
Am J Hematol; 2008 May; 83(5):366-70. PubMed ID: 18181203
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea for hemoglobin E/β-thalassemia: a systematic review and meta-analysis.
Algiraigri AH; Kassam A
Int J Hematol; 2017 Dec; 106(6):748-756. PubMed ID: 28786080
[TBL] [Abstract][Full Text] [Related]
11. Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-β thalassemia - a pilot study from a tertiary care Centre of India.
Jain M; Chakrabarti P; Dolai TK; Ghosh P; Mandal PK; Baul SN; De R
Blood Cells Mol Dis; 2021 May; 88():102544. PubMed ID: 33610115
[TBL] [Abstract][Full Text] [Related]
12. Association of Exon 14 of the
Mohammadi Z; Mohammadi R; Haghpanah S; Moghadam M; Pazhoomand R; Karimi M
Hemoglobin; 2020 Nov; 44(6):406-410. PubMed ID: 33164584
[TBL] [Abstract][Full Text] [Related]
13. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
Yavarian M; Karimi M; Bakker E; Harteveld CL; Giordano PC
Haematologica; 2004 Oct; 89(10):1172-8. PubMed ID: 15477200
[TBL] [Abstract][Full Text] [Related]
14. Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013.
Kosaryan M; Karami H; Zafari M; Yaghobi N
Hemoglobin; 2014; 38(2):115-8. PubMed ID: 24471558
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia.
Hoppe C; Vichinsky E; Lewis B; Foote D; Styles L
Am J Hematol; 1999 Dec; 62(4):221-7. PubMed ID: 10589077
[TBL] [Abstract][Full Text] [Related]
16. Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in β-Thalassemia Intermedia: A Validation Cohort Study.
Kolliopoulou A; Siamoglou S; John A; Sgourou A; Kourakli A; Symeonidis A; Vlachaki E; Chalkia P; Theodoridou S; Ali BR; Katsila T; Patrinos GP; Papachatzopoulou A
Hemoglobin; 2019 Jan; 43(1):27-33. PubMed ID: 31039620
[TBL] [Abstract][Full Text] [Related]
17. Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients.
Bhurani D; Kapoor J; Yadav N; Khushoo V; Agrawal N; Ahmed R; Arora JS; Mehta P
Ann Hematol; 2021 Jun; 100(6):1417-1427. PubMed ID: 33811502
[TBL] [Abstract][Full Text] [Related]
18. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea in the management of thalassemia intermedia.
Karimi M
Hemoglobin; 2009; 33 Suppl 1():S177-82. PubMed ID: 20001623
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea Treated β-Thalassemia Children Demonstrate a Shift in Metabolism Towards Healthy Pattern.
Iqbal A; Ansari SH; Parveen S; Khan IA; Siddiqui AJ; Musharraf SG
Sci Rep; 2018 Oct; 8(1):15152. PubMed ID: 30310134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]